Oncimmune USA LLC revealed on Thursday the availability of a validated finger stick blood collection, the EarlyCDT-Lung test.

The company said the EarlyCDT-Lung test is a simple blood test that aids pulmonologists and other physicians in risk assessment and can detect lung cancer up to four years earlier than other methods. It is highly cost-effective.

According to the company, the EarlyCDT-Lung test finger stick sample collection procedure simply requires the patient to pierce the skin of the finger using the contact activated lancet that is supplied and then collect sufficient blood drops into a small collection tube that is returned to its CLIA-certified laboratory in Kansas in a bag supplied. The result is reported to the physician in two to five days. The EarlyCDT-Lung test may be billed to Medicare and most commercial insurance.

Additionally, the company's finger stick collection now gives physicians and patients the option to collect samples easily in the physician's office or even in the patient's home, thus making the entire process much simpler and quicker. Validation studies showed excellent results correlation between venous and finger stick sampling methods with no loss of signal or efficacy. Patients will still have the option of having a standard venous collection through a phlebotomist if this is their preference.

Oncimmune USA LLC is an early cancer detection company and the US subsidiary of Oncimmune Holdings plc (AIM:ONC.L), headquartered in Nottingham, UK.